22nd Century Group

22nd Century Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of 22nd Century Group (XXII) as of Nov 1, 2026 is 170.12 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 95.66 % — a change of 77.84% (higher).

FCF Conversion

170.12 %

YoY

77.84%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of 22nd Century Group is 2025 170.12 % . FCF Conversion Rate (FCF/EBITDA) of 22nd Century Group was 2024 95.66 % . It decreases by 77.84% higher compared to the previous year.

The 22nd Century Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
237.86 USD
Jan 1, 2019
59.04 USD
Jan 1, 2020
81.90 USD
Jan 1, 2021
73.32 USD
Jan 1, 2022
93.88 USD
Jan 1, 2023
43.05 USD
Jan 1, 2024
95.66 USD
Jan 1, 2025
170.12 USD
The 22nd Century Group FCF Conversion history
YEARFCF ConversionYoY
170.12 %+77.84%
95.66 %+122.21%
43.05 %-54.14%
93.88 %+28.04%
73.32 %-10.47%
81.90 %+38.72%
59.04 %-75.18%
237.86 %+126.61%
104.96 %+16.42%
90.16 %+27.96%
70.45 %+22.46%
57.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

22nd Century Group Stock analysis

What does 22nd Century Group do? 22nd Century Group, Inc. develops biotechnology solutions for tobacco and cannabis plants, focusing on genetic engineering to adjust nicotine levels in tobacco and cannabinoid levels in cannabis. The company creates products like RED SUN and MAGIC cigarettes, which it manufactures, markets, and distributes. It also produces SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA) and offers contract manufacturing for third-party branded tobacco products. The firm's revenue streams include sales of its branded cigarettes, research cigarette production, and contract manufacturing services. The company's primary customers are consumers of its RED SUN and MAGIC cigarette brands, research institutions like NIDA, and third-party tobacco brands seeking contract manufacturing. Its product lines target segments interested in reduced nicotine content for smoking cessation and research purposes. The X-22 smoking cessation aid, featuring very low nicotine (VLN) cigarettes, represents a key product in its portfolio aimed at helping users reduce nicotine dependency. 22nd Century Group's business model revolves around selling its proprietary tobacco products, providing research-grade cigarettes for scientific studies, and fulfilling manufacturing contracts for other brands. The company's focus on genetic engineering for nicotine reduction positions it within the market for less harmful tobacco alternatives, while its contract manufacturing services diversify its revenue sources beyond direct consumer sales. 22nd Century Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 22nd Century Group stock

FCF Conversion Rate (FCF/EBITDA) of 22nd Century Group is 170.12 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of 22nd Century Group changed from 95.66 % to 170.12 %, representing a 77.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) 22nd Century Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s 22nd Century Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — 22nd Century Group

All Key Metrics — 22nd Century Group